Access to Medicines and Vaccines

This open access book is the outcome of a Global Forum on Innovation, Intellectual Property and Access to Medicines held in December 2019 at the Max Plank Instititute in Munich, organised by the South Centre and the Max Plank Institute. The academics and experts from international organisations participating have contributed chapters to this book. The book is for policy makers (in Ministries of Health, Ministries of Trade, Ministries of Foreign Affairs, patent offices), but also relevant for academics (law, trade, public health), on the flexibilities available in the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization to promote access to medicines.

Highly specialised book Inter-disciplinary approach which draws wide interest Topic subject in the context of the Covid-19 pandemic This book is open access, which means that you have free and unlimited access

Autorentext

Prof. Dr. Carlos María Correa is executive director of the South Centre, Geneva. He is a renowned international authority on intellectual property and technology issues.

Professor Correa has worked with the Argentine government and has been the director of the Center for Interdisciplinary Studies on Industrial Property and Economics (CEIDIE) in the Law Faculty at the University of Buenos Aires. He was a member of the UK Commission on Intellectual Property Rights, the Commission on Intellectual Property Rights, Innovation and Public Health established by the World Health Assembly, and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Professor Correa has been a visiting professor in postgraduate courses of several universities and consultant to various regional and international organisations. He has advised several governments on intellectual property, innovation policy and public health. He is the author of several books and numerous articles.

Professor Correa is both a lawyer and economist from the University of Buenos Aires and holds a PhD in Law from the University of Buenos Aires.

Prof. Dr. Dr. h.c. Reto M. Hilty is director at the Max Planck Institute for Competition and Innovation Munich and full professor ad personam at the University of Zurich.

Inhalt

Interpreting the flexibilities under the TRIPS agreement.- Intellectual Property Exhaustion and Parallel Imports of Pharmaceuticals: A Comparative and Critical Review.- Compulsory license and government use.- Access to genome editing technologies.- Bolar exception.- Patent oppositions in India.- Protection of clinical test data.- Courts and Pharmaceutical Patents.- Robust Patent Examination or Deep Harmonization? Cooperation and Work Sharing between Patent Offices .- IPRs, Competition Law and excessive pricing of medicines.- The impact of TRIPS plus rules.- Patent Linkages and its Impact on Access to Medicines.

<p